Permanent scalp alopecia related to breast cancer chemotherapy by sequential fluorouracil/epirubicin/cyclophosphamide (FEC) and docetaxel: A prospective study of 20 patients

Annals of Oncology

Volumn 23, Issue 11, 2012, Pages 2879-2884

  Kluger, N ^a,b   Jacot, W ^a,c   Frouin, E ^a,d   Rigau, V ^a,d   Poujol, S ^a,c   Dereure, O ^a,b   Guillot, B ^a,b   Romieu, G ^a,c   Bessis, D ^a,b  

^a UNIV MONTPELLIER   (France)

^b HÔPITAL SAINT ELOI   (France)

^c CENTRE VAL D AURELLE   (France)

^d GUI DE CHAULIAC HOSPITAL   (France)

Author keywords

Breast cancer; Chemotherapy; FEC docetaxel; Permanent alopecia

Indexed keywords

BIOTIN; CYCLOPHOSPHAMIDE; DEXPANTHENOL; DOCETAXEL; EPIRUBICIN; FLUOROURACIL; METHIONINE; MINOXIDIL; PSORALEN; PYRIDOXINE; SPIRONOLACTONE; VITAMIN;

ADULT; AGED; ALOPECIA; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CAUCASIAN; CLINICAL ARTICLE; DERMATOLOGY LIFE QUALITY INDEX; DISTRESS SYNDROME; FEMALE; FRANCE; HAIR LOSS; HUMAN; HUMAN TISSUE; IRON DEFICIENCY; MALE TYPE ALOPECIA; MENOPAUSE; MULTIPLE CYCLE TREATMENT; PHOTOTHERAPY; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; SCALP HAIR; SKIN BIOPSY; THYROID DISEASE; ZINC DEFICIENCY;

ADULT; AGED; ALOPECIA; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; EPIRUBICIN; FEMALE; FICUSIN; FLUOROURACIL; HUMANS; MIDDLE AGED; MINOXIDIL; PROSPECTIVE STUDIES; SPIRONOLACTONE; TAXOIDS; ULTRAVIOLET THERAPY; VITAMINS;

EID: 84868139064     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds095     Document Type: Article

References (21)

1. Dorr VJ. A practitioner's guide to cancer-related alopecia. Semin Oncol 1998; 25: 562-570.
2. Palamaras I, Misciali C, Vincenzi C et al. Permanent chemotherapy-induced alopecia: a review. J Am Acad Dermatol 2011; 64: 604-606.
3. Baker BW, Wilson CL, Davis AL et al. Busulphan/cyclophosphamide conditioning for bone marrow transplantation may lead to failure of hair regrowth. Bone Marrow Transplant 1991; 7: 43-47.
4. Ljungman P, Hassan M, Bekassy AN et al. Busulfan concentration in relation to permanent alopecia in recipients of bone marrow transplants. Bone Marrow Transplant 1995; 15: 869-871.
5. Tran D, Sinclair RD, Schwarer AP, Chow CW. Permanent alopecia following chemotherapy and bone marrow transplantation. Australas J Dermatol 2000; 41: 106-108.
6. Tosti A, Piraccini BM, Vincenzi C, Misciali C. Permanent alopecia after busulfan chemotherapy. Br J Dermatol 2005; 152: 1056-1058.
7. de Jonge ME, Mathot RA, Dalesio O et al. Relationship between irreversible alopecia and exposure to cyclophosphamide, thiotepa and carboplatin (CTC) in high-dose chemotherapy. Bone Marrow Transplant 2002; 30: 593-597.
8. Machado M, Moreb JS, Khan SA. Six cases of permanent alopecia after various conditioning regimens commonly used in hematopoietic stem cell transplantation. Bone Marrow Transplant 2007; 40: 979-982.
9. Perez-Crespo M, Betlloch I, Ballester I et al. Irreversible alopecia due to busulphan in a 7-year-old girl. Eur J Dermatol 2009; 19: 192-193.
10. Prevezas C, Matard B, Pinquier L, Reygagne P. Irreversible and severe alopecia following docetaxel or paclitaxel cytotoxic therapy for breast cancer. Br J Dermatol 2009; 160: 883-885.
11. Tallon B, Blanchard E, Goldberg LJ. Permanent chemotherapy-induced alopecia: case report and review of the literature. J Am Acad Dermatol 2010; 63: 333-336.
12. Miteva M, Misciali C, Fanti PA et al. Permanent alopecia after systemic chemotherapy: a clinicopathological study of 10 cases. Am J Dermatopathol 2011; 33: 345-350.
13. Roche H, Fumoleau P, Spielmann M et al. Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial. J Clin Oncol 2006; 24: 5664-5671.
14. Camacho-Martinez FM. Hair loss in women. Semin Cutan Med Surg 2009; 28: 19-32.
15. Soules MR, Sherman S, Parrott E et al. Executive summary: Stages of Reproductive Aging Workshop (STRAW). Fertil Steril 2001; 76: 874-878.
16. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19: 210-216.
17. Miller K, Wang M, Gralow J et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007; 357: 2666-2676.
18. Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353: 1659-1672.
19. Reid EE, Haley AC, Borovicka JH et al. Clinical severity does not reliably predict quality of life in women with alopecia areata, telogen effluvium, or androgenic alopecia. J Am Acad Dermatol 2012; 663e97-102.
20. Lemieux J, Maunsell E, Provencher L. Chemotherapy-induced alopecia and effects on quality of life among women with breast cancer: a literature review. Psychooncology 2008; 17: 317-328.
21. Williamson D, Gonzalez M, Finlay AY. The effect of hair loss on quality of life. J Eur Acad Dermatol Venereol 2001; 15: 137-139.